Cagrilintide: The Amylin Analog Behind CagriSema
Cagrilintide is Novo Nordisk's long-acting amylin analog. Most people meet it as the amylin half of CagriSema, but on its own it produced roughly 11.8% weight loss in Phase 3. Here is what the molecule does, what the data shows, and why it matters in the 2026 obesity pipeline.
What Is Cagrilintide?
Cagrilintide is a synthetic, long-acting analog of amylin, a peptide hormone the pancreas releases alongside insulin after a meal. Amylin tells the brain you are full, slows the rate at which the stomach empties, and blunts the post-meal rise in glucagon. Native amylin breaks down in minutes; cagrilintide was engineered to last about a week, which makes once-weekly dosing possible.
Novo Nordisk built cagrilintide as a deliberate complement to its GLP-1 franchise. Because amylin and GLP-1 act through separate receptors, the two can be combined for additive appetite suppression. That logic is the foundation of CagriSema, the cagrilintide plus semaglutide combination now under FDA review.
How Cagrilintide Works: The Amylin Pathway
Amylin signaling is distinct from the GLP-1 system that powers Ozempic, Wegovy, and Mounjaro. Amylin receptors sit in the hindbrain area postrema and connect to satiety circuits in the hypothalamus. When cagrilintide activates them, three things happen: appetite drops, gastric emptying slows, and the body registers fullness on less food.
The practical takeaway is that amylin agonists hit hunger from a different angle than incretin drugs. Stacking an amylin analog on top of a GLP-1 drug recruits a second, independent brake on appetite. This is why combination products outperform either mechanism alone, a pattern also seen with the dual and triple agonists like retatrutide. For more on the hormone biology, see our overview of peptide hormones.
Cagrilintide Monotherapy: The Weight Loss Data
Cagrilintide has real standalone efficacy, even if Novo Nordisk no longer markets it as a solo product. In the Phase 3 REDEFINE 1 trial, cagrilintide monotherapy produced an average body weight reduction of 11.8% at 68 weeks, compared with 2.3% for placebo. About 31.6% of participants on cagrilintide lost at least 15% of their body weight, versus 4.7% on placebo.
The earlier Phase 2 program supports those numbers. In a 26-week, placebo-controlled trial of 706 adults with obesity or overweight plus a weight-related condition, cagrilintide at the top doses produced roughly 10.8% weight loss, beating both placebo (about 3%) and the daily GLP-1 comparator liraglutide 3.0 mg. The trial tested five weekly doses (0.3, 0.6, 1.2, 2.4, and 4.5 mg).
For perspective: 11 to 12% loss is solid but lands below semaglutide (around 15%) and well below tirzepatide (around 21%). Amylin's value is less as a standalone and more as a combination partner.
Cagrilintide vs CagriSema
These two names get confused constantly. Cagrilintide is one molecule, an amylin analog. CagriSema is a fixed-dose combination that puts cagrilintide and semaglutide in a single weekly injection.
The combination wins on efficacy. In REDEFINE 1, CagriSema delivered roughly 22 to 23% weight loss, clearly ahead of cagrilintide's 11.8% or semaglutide's standalone result. Two appetite pathways beat one. That is the entire commercial logic: cagrilintide exists primarily to make the GLP-1 work harder. See the head-to-head in our CagriSema vs tirzepatide comparison.
Cagrilintide vs Semaglutide and Tirzepatide
The cleanest way to think about cagrilintide is by mechanism. Semaglutide is a GLP-1 agonist and tirzepatide is a GIP/GLP-1 dual agonist. Cagrilintide is neither; it is an amylin agonist. Different receptor, different pathway.
On raw weight loss, the incretin drugs win as single agents. But because amylin is mechanistically independent, it does not compete with GLP-1 so much as add to it. That is why the interesting comparisons are not cagrilintide alone against tirzepatide, but CagriSema against tirzepatide and against the triple agonist retatrutide. For a broader map of the category, see all GLP-1 medications and peptides for weight loss.
Cagrilintide Dosing
There is no FDA-approved consumer dosing for cagrilintide because the standalone product is not approved. In clinical trials it was given once weekly by subcutaneous injection with gradual escalation to limit nausea. Phase 2 evaluated 0.3, 0.6, 1.2, 2.4, and 4.5 mg weekly, and 2.4 mg became a reference dose carried into combination work.
Titration matters. Amylin analogs, like GLP-1 drugs, cause the most gastrointestinal trouble when the dose jumps too fast. Trial protocols stepped patients up over several weeks. Any dosing applied to gray-market research material happens without the medical supervision, sterile manufacturing, or dose verification that trial participants had. For general technique context see how to inject peptides and injection sites.
Side Effects and Safety
Cagrilintide's side effect profile tracks closely with the GLP-1 class: nausea, vomiting, diarrhea, and constipation lead the list, mostly mild to moderate, and concentrated during dose escalation. Slowed gastric emptying is the underlying cause, the same reason these drugs suppress appetite in the first place.
Injection-site reactions appear in some patients. Serious adverse events were uncommon in the trials, but long-term safety data for amylin analogs is younger than the GLP-1 record. As with the incretin drugs, gastrointestinal intolerance is the main driver of discontinuation rather than rare serious events.
Regulatory Status and Where to Get It
As of 2026, cagrilintide is not FDA approved as a standalone drug. Novo Nordisk filed for approval of CagriSema, the combination, not cagrilintide by itself. There is no legitimate prescription route to cagrilintide monotherapy.
That leaves only the gray market, where cagrilintide is sold as research material with no quality assurance. The risks mirror every other unapproved peptide: unverified purity, possible contamination, and dosing without oversight. Read research peptides, gray-market risks, and peptide testing and quality before considering anything sold outside a pharmacy.
Cagrilintide in the 2026 Amylin Race
Amylin is one of the most contested targets in obesity medicine right now. Cagrilintide is the most clinically advanced amylin analog, but it is no longer alone: petrelintide and Novo's own amycretin (a single molecule combining amylin and GLP-1 activity) are pushing the category forward. The bet across the industry is that amylin plus incretin combinations will define the next tier of weight loss drugs after the current GLP-1 generation.
For cagrilintide specifically, the strategic role is set: combination partner first, standalone a distant second. Its legacy is likely to be CagriSema rather than a solo launch. Track the rest of the pipeline through mazdutide, survodutide, and retatrutide.
Related Guides
CagriSema
The cagrilintide plus semaglutide combination and its REDEFINE trial data.
Complete GLP-1 Guide
How GLP-1 receptor agonists work and how amylin fits alongside them.
Retatrutide
The triple-hormone agonist leading the next wave of obesity drugs.
Peptides for Weight Loss
The full landscape of peptide and incretin weight loss therapies.
CagriSema vs Tirzepatide
Amylin-GLP-1 combination against the GIP/GLP-1 dual agonist.
All GLP-1 Medications
Every approved and pipeline incretin drug in one place.
Frequently Asked Questions About Cagrilintide
Cagrilintide is a long-acting synthetic amylin analog developed by Novo Nordisk for weight management. Amylin is a hormone co-secreted with insulin by the pancreas that signals fullness. Cagrilintide is dosed once weekly by subcutaneous injection. It is best known as the amylin half of CagriSema, the cagrilintide plus semaglutide combination.
In the Phase 3 REDEFINE 1 trial, cagrilintide monotherapy produced an average of 11.8% body weight reduction at 68 weeks versus 2.3% for placebo, with about 1 in 3 participants (31.6%) losing 15% or more. An earlier Phase 2 monotherapy trial in 706 adults showed roughly 10.8% loss at 26 weeks. That is meaningful but below what semaglutide (about 15%) or tirzepatide (about 21%) achieve as single agents.
No. As of 2026 cagrilintide is not FDA approved as a standalone drug. Novo Nordisk has concentrated its filing strategy on CagriSema, the cagrilintide plus semaglutide combination, rather than seeking approval for cagrilintide by itself. Anyone selling cagrilintide directly to consumers is operating outside the legal supply chain.
Semaglutide is a GLP-1 receptor agonist and tirzepatide is a dual GIP/GLP-1 agonist. Cagrilintide works through a completely separate pathway, the amylin receptor system. Because the mechanism is different, amylin agonists can be stacked on top of GLP-1 drugs for additive effect, which is the entire rationale behind CagriSema.
Cagrilintide is a single molecule, an amylin analog. CagriSema is a fixed-dose combination product that pairs cagrilintide with semaglutide in one weekly injection. CagriSema produces more weight loss (about 22 to 23% in REDEFINE 1) than either component alone because it hits two appetite pathways at once.
The side effect profile resembles GLP-1 drugs: nausea, vomiting, diarrhea, and constipation, mostly mild to moderate and worst during dose escalation. Injection-site reactions can occur. Because amylin slows gastric emptying, gastrointestinal symptoms are the main reason people stop. Long-term safety data on amylin analogs is still maturing.
In trials cagrilintide was given once weekly by subcutaneous injection with gradual dose escalation. Phase 2 tested 0.3, 0.6, 1.2, 2.4, and 4.5 mg weekly, with 2.4 mg emerging as a key dose. There is no FDA-approved consumer dosing because the standalone product is not approved. Any dosing guidance for research-grade material is not medically supervised.
There is no FDA-approved cagrilintide product to buy with a prescription. The drug exists in clinical trials and as gray-market research material sold without quality control or physician oversight, which carries the same risks as other research peptides: unknown purity, contamination, and incorrect dosing. See our coverage of research peptide risks and peptide testing for context.
Amylin is one of the hottest targets in obesity medicine. Cagrilintide is the most advanced amylin analog, but it competes with newer entrants like petrelintide and amycretin. The strategic value of cagrilintide is mostly as a combination partner with semaglutide in CagriSema rather than as a solo drug.